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ObituaryChris Marshall (1949–2015)Chris MarshallChris Marshall, a groundbreaking cancer
scientist and passionate advocate for the
translation of basic scientific discovery to
therapeutic application, died on August
8, 2015. Although he had been unwell for
some time, the news has come as a sad
blow to his many friends and colleagues
in the cancer research community and
beyond. Chris made enormous contribu-
tions to cancer research throughout his
career, from the identification of some of
the first human oncogenes in the early
1980s to the development of new cancer
therapies inwidespreadclinical use today.
He was an enthusiastic collaborator and
a dedicated and caring mentor, guiding
numerous young (andnot so young) scien-
tists to successful careers. His legacy will
live on in his science and in the many peo-
ple that he inspired.
Chris was born in Birmingham on
January 19, 1949, to Lillian and James
Marshall, and he grew up in Coventry,
where he attended King Henry VIII school.
Hewon a scholarship to studyNatural Sci-
ences at Churchill College in Cambridge
and then completed a DPhil in Oxford,
working with Henry Harris on cell hy-
brids—a topic he pursued further with
Sammy Franks at the Imperial Cancer
Research Fund (later known as the Lon-
don Research Institute). These experi-
ments showed Chris that the cancer
phenotype could be recessive —fusions
of normal and tumor cells were not tumor-
igenic—and triggered a lifelong interest in
genes that contribute to the promotion or
inhibition of cancer. To continue these
studies, Chris moved to the Sidney Farber
(nowDana Farber) Cancer Institute at Har-
vard Medical School in Boston to work
with Ruth Sager. These were hectic years
for Chris, who already had a young family,
but they introduced him to the work of
Robert Weinberg and others, who were
transferring oncogenic properties from
transformed to untransformed cells using
DNA transfection. This opened Chris’s
eyes to the fact that cancer genes can
also behave in a dominant way and sowed
the seed for the rest of his scientific career.
In 1980, Chris returned to the UK to
establish his own group within the newly
formed Division of Cell and Molecular
Biology at the Institute of Cancer Research(ICR) in London. He was keen to identify
more human oncogenes and quickly
forged close partnerships with two other
new recruits—Alan Hall and Hugh Pater-
son—thatproved tobeenduringandhighly
productive. Finding oncogenes was not an
easy endeavor and, following a series of
disappointments, Chris and Alan were on
the cusp of giving up. Over Sunday lunch,
they came to an agreement to have one
last attempt, and success finally arrived in
the shape of NRAS—the third member of
the RAS family. This was the beginning
of Chris’s pursuit of RAS and the RAS
pathway.With his collaborators, postdocs,
and students, Chris painstakingly unrav-
eled the mechanisms by which RAS func-
tions to regulate cell proliferation and
migration. He showed that RAS controls
signaling though the ERK/MAP kinase
cascade and, in a characteristic flash of
brilliance, suggested that the first efforts
at cancer genome sequencing should
focus on this pathway.What Chris realized
was that cancers without RAS mutations
are likely to have perturbations elsewhere
in the pathway and, indeed, RAS wild-
type melanomas soon yielded frequent
mutations in BRAF. Chris was working on
RAF at the time and his work underpinned
the development of a BRAF inhibitor
currently in clinical trials. Later, Chris’s
attention turned to the way cells move,Cancer Cell 28, Seand in elegant studies, he showed how
GTPases function to control cell shape
and the mechanism of cell movement.
Chris was a strong advocate for the
translation of scientific discovery into pa-
tient benefit, and he believed that those of
us funded by charitable contributions to
cancer research should focus directly on
questions pertaining to cancer. He kept
this objective firmly in mind as he led the
Science Committee of Cancer Research
UK and played a key role in advising the
charity on their strategy and funding. He
also served as the Director of Research
andHead of the Division of Cancer Biology
at the ICR, and in all of these leadership
roles, he brought wisdom, objectivity, and
an ability to bring out the best in people.
It goes without saying that Chris was an
unusually clever and talented scientist—
he had an insight and intuition that allowed
him to unravel the complexities of biolog-
ical systems and interpret disparate and
perplexing results. Importantly, he was
unconditionally rigorous and exacting,
never cutting corners, never satisfied
with incomplete or ambiguous results.
His dedication to science was a direct
reflection of the fact that he found the
problems he studied fascinating and
endlessly absorbing. I called to congratu-
late him on his 60th birthday to discover
him not in the pub or in a fancy
restaurant, but in the cold room doing
an orthophosphate-labeling experiment.
This was not an isolated incident, as his
family will attest, and those of us who
were lucky enough to work with him were
easily swept along with his excitement
and enthusiasm.
Indeed, Chris trained a number of
outstanding scientists who have them-
selves become leaders in cancer
research—a testimony to his ability to
mentor and inspire. Chris set high stan-
dards, but always led by example. He
could be demanding, even uncompro-
mising,but hewasunfailingly kind,encour-
aging, and supportive. He was immensely
proud of the achievements of his trainees,
from publishing papers to producing ba-
bies. His office was festoonedwith photos
of the progeny of his scientific family—a
chaotic mess that was faithfully repro-
duced in an exhibition at the Scienceptember 14, 2015 ª2015 Elsevier Inc. 271
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ObituaryMuseum in London intended to represent
the life of a modern scientist.
Chris’s work was recognized by
numerous prizes and honors. He was
elected as a Fellow of the Royal Society,
The European Academy of Sciences, the
Academy of Medical Sciences, and the
European Molecular Biology Organiza-
tion. He won the Novartis Medal of the
Biochemical Society, the Buchanan
Medal of the Royal Society, the Biochem-
ical Society Centenary Award, and the
Cancer Research UK Lifetime Achieve-
ment Award.
Chris was certainly a brilliant scientist,
but he was also tremendously good fun,
with an impish and irreverent sense of hu-272 Cancer Cell 28, September 14, 2015 ª20mor. He developed many scientific friend-
ships, and our sadness at losing Chris has
been given added poignancy by the sud-
den death of his especially close friend
and colleague, Alan Hall, only three
months ago. Chris and Alan will be
remembered as one of the great scientific
partnerships of modern times.
Outside the lab, Chris pursued a pas-
sion for cycling, and even deep scientific
discussions could be interrupted by the
appearance of a nice bike. He took great
pleasure from riding and racing with the
Norwood Paragon cycling club.
I had the good fortune to be Chris’s
first postdoc, joining him soon after he
started at the ICR in the early 1980s.15 Elsevier Inc.Chris was my teacher, my mentor, my
hero, and my dear friend. The world has
lost a brilliant and dedicated scientist,
and science has lost a passionate and
steadfast friend.
Chris is survived by his second wife
Lesley; his first wife Vivien and their three
children Joe, Lucy, and Francis; and his
four grandchildren, of whom he was
immeasurably proud.Karen H. Vousden1,*
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